Announcements Trials

Browse Landscape

Phase

Phase 4 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Polycythemia Vera 3 Thrombocythemia, Essential 2 Philadelphia Chromosome 2 Neoplasm Metastasis 2 Myeloproliferative Disorders 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Brain Neoplasms 2 Skin Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Leukemia 1 Glioma 1 Colonic Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms, Male 1 Breast Neoplasms 1 Blast Crisis 1

Interventions

Gemcitabine 53 Bevacizumab 52 Cyclophosphamide 49 Docetaxel 42 Carboplatin 40 pembrolizumab 37 Paclitaxel 36 Fluorouracil 36 Cisplatin 35 Radiotherapy 31 Oxaliplatin 31 Capecitabine 29 Irinotecan 28 Dexamethasone 27 Leucovorin 25 Cetuximab 25 Nivolumab 24 Doxorubicin 22 Drug Therapy 21 Erlotinib Hydrochloride 20 Pemetrexed 19 durvalumab 18 trametinib 17 fludarabine 16 atezolizumab 16 Trastuzumab 16 Sunitinib 16 Rituximab 16 Prednisone 16 Sorafenib 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms × peginterferon alfa-2a × Clear all

NCT00178763 2011-03-03

FR-WB-TT

The University of Texas Health Science Center, Houston

Phase 2 Unknown

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡